Physician profile
John M Huser
NPI 1699750554
$599.22
in general payments reported to CMS, 2019-2025
15 companies · $73.73 in 2025
The $73.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.29 · 2020: $29.29 · 2021: $111 · 2022: $115 · 2023: $75.95 · 2024: $118 · 2025: $73.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $267.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.72 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $114.76 | 2019-2024 | Rotateq, Vaxneuvance, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $71.08 | 2023-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $52.29 | 2020-2025 | Rybelsus, Ozempic |
| Edwards Lifesciences Corporation | $37.43 | 2024 | |
| Phathom Pharmaceuticals, INC. | $36.69 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $27.63 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $21.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.63 | 2021 | |
| Glaxosmithkline, LLC. | $16.49 | 2023 | Trelegy Ellipta |
| Abbvie INC. | $16.02 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $15.38 | 2025 | Zoryve |
| Amgen INC. | $15.36 | 2023 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $15.32 | 2022 | |
| Lilly USA, LLC | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Huser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.